1. Living-Donor Lung Transplantation for Post–COVID-19 Respiratory Failure
- Author
-
Itsuki Yuasa, Satona Tanaka, Daisuke Nakajima, Hiroshi Date, Miki Nagao, Masatsugu Hamaji, Yojiro Yutaka, Jumpei Takamatsu, Kazuhiro Yamazaki, and Akihiro Ohsumi
- Subjects
Pulmonary and Respiratory Medicine ,Mechanical ventilation ,Coronavirus disease 2019 (COVID-19) ,business.industry ,medicine.medical_treatment ,Case Report ,law.invention ,Collapsed Lung ,surgical procedures, operative ,Respiratory failure ,law ,Anesthesia ,medicine ,Extracorporeal membrane oxygenation ,Cardiopulmonary bypass ,Lung transplantation ,Surgery ,Respiratory function ,Cardiology and Cardiovascular Medicine ,business - Abstract
We report the first case of coronavirus disease 2019 (COVID-19)-associated respiratory failure requiring urgent living-donor lobar lung transplantation (LDLLTx). A 57-year-old woman with a positive viral status developed severe hypoxia requiring extracorporeal membrane oxygenation (ECMO). Her respiratory function deteriorated, with almost totally collapsed lungs. All of her other organs functioned well. After 104 days on ECMO, she received urgent LDLLTx under cardiopulmonary bypass. The grafts worked well, and she was weaned off cardiopulmonary bypass after reperfusion. LDLLTx is an option for selected patients with post-COVID-19 end-stage respiratory failure. Coronavirus disease 2019 (COVID-19) has spread worldwide since December 2019 due to the unprecedented pandemic.1 Patients with end-stage COVID-19-related respiratory failure require mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO). In some countries, lung transplantation (LTx) has become a treatment option for irreversible lung function deterioration.2,3 We report the first successful case of severe respiratory failure caused by COVID-19 treated with urgent living-donor lobar lung transplantation (LDLLTx).
- Published
- 2022
- Full Text
- View/download PDF